Protalix BioTherapeutics, Inc. Share Price
PLXProtalix BioTherapeutics, Inc. Stock Performance
Open $1.78 | Prev. Close $1.74 | Circuit Range N/A |
Day Range $1.73 - $1.79 | Year Range $1.32 - $3.10 | Volume 24,989 |
Average Traded $1.77 |
Protalix BioTherapeutics, Inc. Share Price Chart
About Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. It operates in the United States, Australia, Canada, Israel, Brazil, Russia, and Turkey. The company is headquartered in Hackensack. New Jersey.
Protalix BioTherapeutics, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
06-Jan-26 | $1.78 | $1.76 | +0.00% |
06-Jan-26 | $1.78 | $1.76 | -1.12% |
05-Jan-26 | $1.76 | $1.78 | +2.29% |
02-Jan-26 | $1.83 | $1.75 | -2.79% |
31-Dec-25 | $1.76 | $1.79 | +2.87% |
30-Dec-25 | $1.76 | $1.75 | -2.24% |
29-Dec-25 | $1.78 | $1.78 | -0.83% |